Abstract #2308

Differentiating glioma recurrence and pseudoprogression by APTw CEST MRI

Kianush Karimian-Jazi^1,2, Noah Enbergs¹, Evgeny Golubtsov¹, Katharina Schregel¹, Johannes Benedikt Ungermann¹, Hannah Fels-Palesandro¹, Daniel Schwarz¹, Volker Sturm¹, Julius M Kernbach¹, David Batra³, Franziska Maria Ippen^3,4, Irada Pflüger¹, Nikolaus von Knebel Doeberitz⁵, Sabine Heiland¹, Michael Platten^6,7, Frank Winkler^3,8, Wolfgang Wick^3,8, Daniel Paech⁹, Martin Bendszus¹, and Michael Oliver Breckwoldt^1,6

¹Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany, ²German Cancer Research Center, Heidelberg, Germany, ³Neurology, University Hospital Heidelberg, Heidelberg, Germany, ⁴German Consortium for Translational Cancer Research, German Cancer Research Center, Heidelberg, Germany, ⁵Division of Radiology, German Cancer Research Center, Heidelberg, Germany, ⁶Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany, ⁷Department of Neurology, Medical Faculty Mannheim, Mannheim, Germany, ⁸Clinical Cooperation Unit Neurooncology, German Cancer Research Center, Heidelberg, Germany, ⁹Division of Neuroradiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States

Synopsis

Keywords: CEST / APT / NOE, CEST & MT, Glioma

Motivation: Recurrent gliomas are treatment-resistant due to metabolic and molecular heterogeneity, posing challenges for accurate monitoring with conventional MRI.

Goal(s): This study aims to evaluate Amide Proton Transfer weighted (APTw) CEST MRI as an imaging biomarker to better assess glioma heterogeneity and differentiate progression from pseudoprogression (PsPD).

Approach: A prospective, single-center trial of 371 glioma patients identified 30 with recurrence and 12 with PsPD. Standard MRI sequences and APTw imaging were performed, with semi-automated segmentation and quantitative analysis.

Results: APTw values distinguished progressive disease from PsPD, revealed metabolic hotspots, and detected resection cavity changes at recurrence, underscoring APTw’s clinical utility in neuro-oncological monitoring.

Impact: This study highlights APTw-CEST MRI's value as an imaging biomarker, aiding clinicians in differentiating progression from pseudoprogression. It enables targeted treatment strategies and opens new research into metabolic imaging for personalized glioma management, enhancing patient care and guiding therapy decisions.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.